News and Announcements
Soar’s token generation event starts in just one week
- Published November 14, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Soar are excited to announce that their Token Generation Event will start in just one week.
The Soar Token Generation Event will start on November 19th at 8am (CST) and will run until the 3rd of December.
The event will be hosted on Tokeneed’s website.
https://www.youtube.com/watch?v=S1Wdm5nuulY&feature=youtu.be
Soar will also be launching four reward giveaways prior to the Token Generation Event (TGE).
About Soar
Soar is a decentralised global platform for the distribution and monetisation of drone content. Initially, the Soar platform is designed to offer a democratised that connects customers with content creators in a secure, trustless and distributed community.
However, this isn’t the end-game. Progressively, by aggregating the content collected from thousands of drone operators, Soar will in due course create a dynamic database for the world’s first super-map at an unprecedented level of detail. All connected using blockchain technology to connect and share data.
Company Updates
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
Backed By Leading Investment Groups and Family Offices
